SOPHiA GENETICS (NASDAQ: SOPH) CPO discloses initial equity holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief People Officer Manuela Valente filed an initial statement of beneficial ownership. She reports direct ownership of 152,759 ordinary shares, including 67,994 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time, subject to continued service.
Valente also reports several share option awards over ordinary shares with exercise prices ranging from 3.2000 to 18.0000 per share and expiration dates between 2029 and 2035. These options cover underlying blocks of 10,000, 20,000, 47,170, 92,937, 160,061 and 119,318 ordinary shares, reflecting her equity-based compensation position rather than new market transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Valente Manuela
Role
Chief People Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 10,000 shares (Direct);
Ordinary Shares — 152,759 shares (Direct)
Footnotes (1)
- Includes 67,994 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 1,690 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 18,917 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 20,381 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 27,006 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027. The share options are fully vested and exercisable. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.
FAQ
What does Manuela Valente’s Form 3 filing for SOPH show?
The Form 3 shows Chief People Officer Manuela Valente’s existing equity holdings in SOPHiA GENETICS SA. It lists ordinary shares she owns directly, restricted stock units that may settle into shares, and multiple share option awards with specified exercise prices and expiration dates.
Are there any restricted stock units (RSUs) reported in SOPH’s Form 3 filing?
Yes. The filing notes 67,994 ordinary shares issuable upon settlement of four RSU grants. Each RSU represents a right to receive one ordinary share, with vesting schedules running in monthly or quarterly installments through 2028, conditioned on continued service with SOPHiA GENETICS SA.
Does Manuela Valente’s Form 3 for SOPH show stock purchases or sales?
The summarized data show no reported purchases or sales, only holdings. The entries describe existing ordinary share ownership, outstanding restricted stock units, and outstanding share options, consistent with an initial statement of beneficial ownership rather than a record of recent trading activity.